Literature DB >> 19126537

p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons.

Miao Tan1, Wendy M Walwyn, Christopher J Evans, Cui-Wei Xie.   

Abstract

Formation of receptor complexes between micro-opioid and alpha2A-adrenergic receptors has been demonstrated in transfected cells. The functional significance and underlying mechanisms of such receptor interactions remain to be determined in neuronal systems. We examined functional interactions between endogenous micro and alpha2A receptors in mouse dorsal root ganglion neurons. Acute application of the micro agonist [D-Ala2,N-MePhe4, Gly-ol5]enkephalin (DAMGO) or the alpha2 agonist clonidine inhibited voltage-gated Ca2+ currents in these neurons. Prolonged treatment with either DAMGO or clonidine induced a mutual cross-desensitization between micro and alpha2A receptor-mediated current inhibition. The cross-desensitization was closely associated with simultaneous internalization of micro and alpha2A receptors. Morphine, a mu agonist triggering little mu receptor endocytosis, induced neither cross-desensitization nor internalization of alpha2A receptors. Furthermore, inhibition of p38 MAPK prevented the cross-desensitization as well as cointernalization of micro and alpha2A receptors. Changes in receptor trafficking profiles suggested that p38 MAPK activity was required for initiating micro receptor internalization and maintaining possible micro-alpha2A association during their cointernalization. Finally, the micro-alpha2A cross-desensitization was absent in dorsal root ganglion neurons lacking beta-arrestin 2. These findings demonstrated p38 MAPK- and beta-arrestin 2-dependent cross-regulation between neuronal micro and alpha2A receptors. By promoting receptor cross-desensitization and cointernalization, such functional interactions may serve as negative feedback mechanisms triggered by prolonged agonist exposure to modulate the signaling of functionally related G protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126537      PMCID: PMC2649085          DOI: 10.1074/jbc.M806742200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Oligomerization of G-protein-coupled transmitter receptors.

Authors:  M Bouvier
Journal:  Nat Rev Neurosci       Date:  2001-04       Impact factor: 34.870

2.  Heterodimerization of mu and delta opioid receptors: A role in opiate synergy.

Authors:  I Gomes; B A Jordan; A Gupta; N Trapaidze; V Nagy; L A Devi
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

3.  Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3.

Authors:  P H McDonald; C W Chow; W E Miller; S A Laporte; M E Field; F T Lin; R J Davis; R J Lefkowitz
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

Review 4.  GPCR monomers and oligomers: it takes all kinds.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Trends Neurosci       Date:  2008-01-15       Impact factor: 13.837

5.  The stress-induced MAP kinase p38 regulates endocytic trafficking via the GDI:Rab5 complex.

Authors:  V Cavalli; F Vilbois; M Corti; M J Marcote; K Tamura; M Karin; S Arkinstall; J Gruenberg
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

6.  The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins.

Authors:  S Uddin; F Lekmine; N Sharma; B Majchrzak; I Mayer; P R Young; G M Bokoch; E N Fish; L C Platanias
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

7.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

8.  Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor.

Authors:  P Y Law; L J Erickson; R El-Kouhen; L Dicker; J Solberg; W Wang; E Miller; A L Burd; H H Loh
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

9.  SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Authors:  D C Underwood; R R Osborn; S Bochnowicz; E F Webb; D J Rieman; J C Lee; A M Romanic; J L Adams; D W Hay; D E Griswold
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-11       Impact factor: 5.464

10.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation.

Authors:  B A Jordan; N Trapaidze; I Gomes; R Nivarthi; L A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  23 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.

Authors:  Michael R Bruchas; Abigail G Schindler; Haripriya Shankar; Daniel I Messinger; Mayumi Miyatake; Benjamin B Land; Julia C Lemos; Catherine E Hagan; John F Neumaier; Albert Quintana; Richard D Palmiter; Charles Chavkin
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

3.  Src family kinases mediate the inhibition of substance P release in the rat spinal cord by μ-opioid receptors and GABA(B) receptors, but not α2 adrenergic receptors.

Authors:  Guohua Zhang; Wenling Chen; Juan Carlos G Marvizón
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

Review 4.  Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Authors:  Wendy M Walwyn; Karen A Miotto; Christopher J Evans
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

5.  GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.

Authors:  Lionel Moulédous; Carine Froment; Stéphanie Dauvillier; Odile Burlet-Schiltz; Jean-Marie Zajac; Catherine Mollereau
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

6.  Heterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells.

Authors:  Kévin Carayon; Lionel Moulédous; Anne Combedazou; Serge Mazères; Evert Haanappel; Laurence Salomé; Catherine Mollereau
Journal:  J Biol Chem       Date:  2014-09-02       Impact factor: 5.157

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 8.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

9.  Functional characterization of G-protein-coupled receptors: a bioinformatics approach.

Authors:  L Tovo-Rodrigues; A Roux; M H Hutz; L A Rohde; A S Woods
Journal:  Neuroscience       Date:  2014-07-02       Impact factor: 3.590

10.  Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.

Authors:  Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.